Seattle, United States
SEngine Precision Medicine, founded in 2015, is pioneering advances in cancer treatment by employing 3D organoid technology combined with proprietary algorithms. Positioned at the intersection of Biotechnology and Health Care, SEngine's commitment to precision medicine is evident through its focus on functional screening, genomics, robotics, cancer organoid cultures, and bioinformatics.
Their approach is revolutionizing the development of precise, less toxic, and more effective cancer therapies, while also providing essential data to pharmaceutical companies, thus expediting drug discovery. SEngine’s CLIA certification underscores its readiness to receive and process clinical samples, further enhancing its contribution to oncology.
The company is headquartered in the United States and most recently secured a $10.00M Series A investment on 28 July 2022, with key investors including Bangarang Group, Washington Research Foundation, Vincere Capital, and Alethea Capital Management.
